u104

U-104 (NSC-213841) is an effective carbonic anhydrase (CA) inhibitor for CA IX( Ki=45.1 nM) and CA XII(Ki=4.5 nM).

(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.

(R)-STU104 is a novel TAK1-MKK3 protein-protein interaction (PPI) inhibitor that inhibits TNF-α and suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signalling pathway by binding to MKK3 and disrupting TAK1 phosphorylation of MKK3. (R)-STU104 is a candidate compound for the treatment of ulcerative colitis.

Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

NEU-1045 is a T. brucei proliferation inhibitor, and is a promising lead with cross-pathogen activity. NEU-1045 inhibited T. brucei, T. cruzi, and L. major proliferation with good potency (T. brucei EC50 = 0.37 μM; T. cruzi EC50 = 2.8 μM; L. major EC50 =

U 104489 (PNU-104489) is a novel specific inhibitor of human immunodeficiency virus 1 (HIV-1), showing effective activity against BHA-P-resistant HIV-1MF.

SLU-10482, an antiparasitic agent, effectively reduces C. parvum parasitic load in HCT-8 cells with an EC50 value of 0.07 µM. It exhibits lower affinity for human ether-a-go-go (hERG; Kd = 43 µM) compared to its counterpart, SLU-2633. When administered in vivo at dosages of 5 and 15 mg/kg twice daily, SLU-10482 significantly decreases fecal oocyst counts in mice infected with C. parvum.